La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Xspray Pharma Gestion

Gestion contrôle des critères 2/4

Le PDG Xspray Pharma's est Per Andersson, nommé en Jan2006, a un mandat de 18.58 ans. La rémunération annuelle totale est SEK 3.74M, composée du salaire de 70.5% et des bonus 29.5%, y compris les actions et options de la société. détient directement 0.57% des actions de la société, d'une valeur de SEK 9.74M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.8 ans et 5.3 ans.

Informations clés

Per Andersson

Directeur général

SEK 3.7m

Rémunération totale

Pourcentage du salaire du PDG	70.5%
Durée du mandat du directeur général	18.8yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	5.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Per Andersson a-t-elle évolué par rapport aux bénéfices de Xspray Pharma?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-SEK 215m
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 4m	SEK 3m	-SEK 180m
Sep 30 2023	n/a	n/a	-SEK 180m
Jun 30 2023	n/a	n/a	-SEK 170m
Mar 31 2023	n/a	n/a	-SEK 148m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 132m
Sep 30 2022	n/a	n/a	-SEK 128m
Jun 30 2022	n/a	n/a	-SEK 114m
Mar 31 2022	n/a	n/a	-SEK 102m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 97m
Sep 30 2021	n/a	n/a	-SEK 60m
Jun 30 2021	n/a	n/a	-SEK 57m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 52m
Sep 30 2020	n/a	n/a	-SEK 56m
Jun 30 2020	n/a	n/a	-SEK 55m
Mar 31 2020	n/a	n/a	-SEK 49m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 46m
Sep 30 2019	n/a	n/a	-SEK 41m
Jun 30 2019	n/a	n/a	-SEK 34m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 17m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 14m

Rémunération vs marché: La rémunération totale de Per ($USD 365.76K ) est dans la moyenne des entreprises de taille similaire sur le marché Swedish ($USD 467.77K ).

Rémunération et revenus: La rémunération de Per a augmenté alors que l'entreprise n'est pas rentable.

PDG

Per Andersson (57 yo)

18.8yrs

Titularisation

SEK 3,743,000

Compensation

Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Per Andersson	Chief Executive Officer	18.8yrs	SEK 3.74m	0.57% SEK 9.4m
Mustafa Demirbüker	Co-Founder and Science Director	no data	pas de données	pas de données
Niklas Adenborg	Chief Financial Officer	less than a year	pas de données	pas de données
Linda Glimberg	Chief Operating Officer	less than a year	pas de données	0.0053% SEK 87.0k
Kerstin Hasselgren	Senior Advisor & Head of IR	less than a year	pas de données	0.024% SEK 398.8k
Charlotta Liljebris	Senior Vice President of Research & Development	6.8yrs	pas de données	0.0089% SEK 145.1k
Edward Jordan	Chief Commercial Officer	1.1yrs	pas de données	pas de données
Anette Abrahamsson	Senior Vice President of Regulatory Affairs	less than a year	pas de données	0.0044% SEK 72.5k
Christer Hallgren	Senior Vice President of Intellectual Property	6.8yrs	pas de données	0.089% SEK 1.5m

0.9yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de XSPRAY n'est pas considérée comme expérimentée (ancienneté moyenne 0.8 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Maris Hartmanis	Independent Director	9.8yrs	SEK 323.00k	0.092% SEK 1.5m
Carl-Johan Spak	Independent Director	9.8yrs	SEK 270.00k	pas de données
Anders Ekblom	Chairman	3.4yrs	SEK 510.00k	1.71% SEK 27.9m
Torbjörn Koivisto	Independent Director	7.8yrs	SEK 253.00k	pas de données
Christine Lind	Independent Director	5.4yrs	SEK 270.00k	pas de données
Anders Bladh	Director	3.4yrs	SEK 253.00k	2.49% SEK 40.7m
Robert Molander	Independent Director	2.4yrs	SEK 218.00k	0.030% SEK 483.5k

5.4yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de XSPRAY sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).

Xspray Pharma Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Recent updates

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

New major risk - Financial position

Director recently bought kr4.8m worth of stock

Price target decreased by 24% to kr91.50

New major risk - Share price stability

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Director recently bought kr143k worth of stock

Now 32% undervalued

Now 23% undervalued

Price target decreased by 11% to kr107

New minor risk - Share price stability

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

New minor risk - Share price stability

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Revenue and earnings growth

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR

Director recently bought kr2.1m worth of stock

Independent Director exercised options to buy kr97k worth of stock.

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Price target decreased by 21% to kr106

Chief Executive Officer recently sold kr2.2m worth of stock

Director recently bought kr135k worth of stock

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Price target decreased to kr116

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Price target decreased to kr116

No longer forecast to breakeven

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Independent Chairman of the Board Michael Jensen has left the company

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

New 90-day low: kr113

Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

New 90-day low: kr114

Chief Executive Officer exercised options and sold kr3.6m worth of stock

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

New 90-day low: kr127

Xspray Pharma Announces Results from Additional Bioequivalence Study

Xspray Pharma’S Hynap-Nilo Receives Fda Orphan Drug Designation for the Treatment of Chronic Myeloid Leukemia

New 90-day high: kr196

Xspray Pharma AB (publ) Decides to Await the Result of Two Ongoing Clinical Studies Before Submitting Its Anda Application